<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02986529</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-C1503</org_study_id>
    <nct_id>NCT02986529</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects</brief_title>
  <official_title>A Double-blind, Randomized, Three-period, Three-way Crossover Design, Placebo Controlled Single Dose Study to Assess the Bioavailability of Sodium Oligo-mannurarate (GV-971) Capsule 150 mg, 300mg, 450mg in Healthy Chinese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Greenvalley Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Greenvalley Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      To evaluate the Bioavailability for GV-971 capsules of 150 mg, 300mg, and 450mg after
      administration of single oral doses of 900mg in healthy Male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">February 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - maximum observed concentration, is obtained directly from the plasma concentration curve</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last-the area under the concentration-time curve from zero to the time of the last measurable concentration; computed using the linear trapezoidal rule</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞-the area under the concentration-time curve from zero to the infinity, computed as AUC0-∞=AUC0-last+Clast/λz (λz is the terminal phase rate constant)</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>GV-971 150mg/capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>900mg, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GV-971 300mg/capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900mg, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GV-971 450mg/capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900mg, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GV-971</intervention_name>
    <arm_group_label>GV-971 150mg/capsule</arm_group_label>
    <arm_group_label>GV-971 300mg/capsule</arm_group_label>
    <arm_group_label>GV-971 450mg/capsule</arm_group_label>
    <other_name>Sodium Oligo-mannurarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects;

          2. Age：≥18 and ≤45 on the date signing informed consent

          3. Body mass index (BMI): 18-25 kg/m2 and the weight ≥50 kg；

          4. Subjects are able to understand the study procedures and methods, and willing to
             strictly comply with the protocol and give written informed consent.

        Exclusion Criteria:

        A subject will be excluded if the answer to any of the following criteria is &quot;yes&quot;:：

          1. Clinically significant abnormalities in physical examination and laboratory test
             results or 12-lead ECG, etc. in screening;

          2. Clinically significant abnormalities in Chest X-ray or abdominal B-ultrasound
             examination

          3. Positive serology screen for Hepatitis B( HBsAg), Hepatitis C(HCV), HIV and USR
             unheated serum reagin test.

          4. Smoking more than 10 cigarettes a day, drugs or alcohol abuse within 6 months prior to
             screening

          5. Participation in any investigational drug or medical instrument study within 3months
             prior to screening, participation in 3 and more than 3 drug tests in a recent year;

          6. Serious infection, trauma and major surgery within 4weeks prior to screening;

          7. Blood donation of ≥400 mL or severe blood lose and the volume of blood loss ≥400 mL
             within 4 weeks prior to screening, receiving blood transfusion treatment within 8
             weeks prior to screening ;

          8. Use of any prescription medicine or herbal remedy, over the counter medication or
             dietary supplements such as vitamin, calcium within 2 weeks prior to screening.

          9. Use of heparin, alginic sodium diester , mannose ester within 4 weeks prior to
             screening；

         10. Vegetarian or person with dietary restrictions

         11. Subjects able to father a child are unwilling to use highly effective physical form of
             birth control from the trial period until 3 months after the completion of study.

         12. With diseases which could impact on the absorption, distribution, metabolism and
             excretion (ADME) of study drugs or protocol adherence in the opinion of the
             investigator (such medical disorder/disease may relate to ccardiovascular, liver,
             kidney, digestive, immune, blood, endocrine, metabolic, cancer, neuropsychiatric,etc
             );

         13. Subjects may be allergic to GV-971 in the opinion of the investigator.

         14. Any other reasons that the subject is not eligible for participation in the study in
             the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phase-I Clinical Research Unit at Shanghai Xuhui Center hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

